诚信认证：
工商注册信息已核实！
Voxelotor (GBT440)，1446321-46-5，10mM in DMSO
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 总代理 | 中国 | 现货 |
性能特点
InformationVoxelotor (GBT440, GTx011) is a novel small moleculehemoglobin modifierwhich increase
| 货号 | 规格 | CAS号 | 价格 | 操作 |
|---|---|---|---|---|
| V421642-1ml | 1ml | 1446321-46-5 | ￥399.90 | 询底价 |
中文名：Voxelotor (GBT440)
英文名：Voxelotor (GBT440)
英文别名：Voxelotor|1446321-46-5|Oxbryta|GBT440|GBT 440|GBT-440|GTX-011|Hemoglobin Modulators-1|2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde|Voxelotor [USAN]|3ZO554A4Q8|GBT-440(Voxelotor)|2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)
纯度：10mM in DMSO
货号：V421642
Cas号：1446321-46-5
存储温度：-80℃储存
产品介绍：
Information
Voxelotor (GBT440, GTx011) is a novel small moleculehemoglobin modifierwhich increases hemoglobin oxygen affinity.
In vitro
GBT440 is a new potent allosteric effector of sickle cell hemoglobin that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. GBT440 inhibits these isozymes(CYP 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4) with IC50 ranging from 7.9 to 148 μM. It is not a substrate for either P-gp or BCRP transporters It binds to the N-terminal a chain of Hb
In vivo
GBT440 has favorable oral bioavailability of 60, 37, and 36% in rats, dogs, and monkeys, respectively, with similar blood and plasma half-lives of approximately 20 h each. T1/2 value of GBT440 in all animal species is significantly shorter than the T1/2 of red blood cells (∼20 days), which supports that binding of GBT440 to hemoglobin is a reversible process. GBT440 is currently in Phase 3 clinical trials (NCT03036813) in SCD patients GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. In a murine model of SCD, GBT440 extends the half-life of RBCs, reduces reticulocyte counts and prevents ex vivo RBC sickling. Importantly, oral dosing of GBT440 in animals demonstrates suitability for once daily dosing in humans and a highly selective partitioning into RBCs, which is a key therapeutic safety attribute. GBT440 shows dose proportional PK, a terminal half-life of 1.5-3 d.
Cell Research(from reference)
Concentrations：0, 300, 600, 1000 μM
查看阿拉丁官网此产品相关对应页面：https://www.aladdin-e.com/zh_cn/V421642.html
Voxelotor (GBT440)，1446321-46-5，10mM in DMSO信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于Voxelotor (GBT440)，1446321-46-5，10mM in DMSO报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途
